Ultragenyx Pharmaceutical (RARE) Price & Analysis

Compare

940 Followers

RARE Stock Chart & Stats

Day’s Range― - ―

52-Week Range$25.81 - $60.37

Previous CloseN/A

Volume75.38K

Average Volume (3M)2.58M

Market Cap

$2.73B

Enterprise Value$3.97B

Total Cash (Recent Filing)$487.58M

Total Debt (Recent Filing)$11.77M

Price to Earnings (P/E)―

Beta1.24

Next Earnings

Nov 04, 2025

EPS Estimate

-1.24

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-1.17

Shares Outstanding94,542,040

10 Day Avg. Volume2,067,600

30 Day Avg. Volume2,581,999

Financial Highlights & Ratios

PEG Ratio0.28

Price to Book (P/B)14.92

Price to Sales (P/S)6.80

P/FCF Ratio-9.03

Enterprise Value/Market Cap1.45

Enterprise Value/Revenue6.51

Enterprise Value/Gross Profit7.63

Enterprise Value/Ebitda-8.79

Forecast

1Y Price Target

$84.31

Price Target Upside191.53% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering16

Bulls Say, Bears Say

Bulls Say

Analyst RatingAnalyst reiterates an 'Outperform' rating, expecting investor focus to shift to the promising apazunersen program.

Clinical TrialsUltragenyx's Aspire study with apazunersen reached full enrollment, demonstrating strong interest and need for treatment in Angelman syndrome.

Market PotentialUltragenyx's flagship CRYSVITA franchise is believed to be capable of achieving peak annual sales totaling over $3 billion.

Bears Say

Clinical UncertaintySetrusumab's probability of success has been lowered to 55% due to increased clinical uncertainty.

Market DelayThe UX111 launch in the US and EU has been delayed to 2027 and 2028, respectively, due to regulatory issues.

Regulatory ChallengesThe FDA issued a complete response letter for UX111 due to concerns related to chemistry, manufacturing, and controls.

Ultragenyx Pharmaceutical News

Ultragenyx reports Q2 EPS ($1.17), consensus ($1.32)

Reports Q2 revenue $166.5M, consensus $161.37M. “In the first half of the year, we delivered 20% revenue growth...

3d ago

RARE

Ultragenyx backs FY25 revenue view $640M-$670M, consensus $649.53M

The company said, “Ultragenyx (RARE) reaffirmed its revenue guidance for 2025. Total revenues are expected to grow approximately...

3d ago

RARE

Ultragenyx completes enrollment of GTX-102 trial

Ultragenyx (RARE) announced that the Phase 3 Aspire study evaluating GTX-102 as a treatment for Angelman Syndrome is...

8d ago

RARE

Ultragenyx assumed with a Buy at H.C. Wainwright

H.C. Wainwright assumed coverage of Ultragenyx (RARE) with a Buy rating and $80 price target The firm sees...

11d ago

RARE

Ultragenyx participates in a conference call with JPMorgan

JPMorgan discusses with management Setrusumab considerations heading into ORBIT/COSMIC and provides updates on YE25 on a conference call...

25d ago

RARE

Ultragenyx price target lowered to $79 from $80 at BofA

BofA lowered the firm’s price target on Ultragenyx (RARE) to $79 from $80 and keeps a Buy rating...

25d ago

RARE

Ultragenyx announces Health Canada extended approval of Evkeeza

Ultragenyx (RARE) Pharmaceutical announced that Health Canada has extended the approval of Evkeeza as an adjunct to diet...

25d ago

RARE

Ultragenyx price target lowered to $55 from $65 at Morgan Stanley

Morgan Stanley lowered the firm’s price target on Ultragenyx (RARE) to $55 from $65 and keeps an Overweight...

25d ago

RARE

Ultragenyx falls 4% to $28.41 after FDA rejection letter for gene therapy

17:19 EDT Ultragenyx (RARE) falls 4% to $28.41 after FDA rejection letter for gene therapy Published first on...

28d ago

RARE

Ultragenyx trading resumes

17:00 EDT Ultragenyx (RARE) trading resumes Published first on TheFly – the ultimate source for real-time, market-moving breaking...

28d ago

RARE

Ultragenyx Pharmaceutical’s Promising Growth and Financial Outlook: Analyst Recommends Buy

William Blair analyst Sami Corwin has maintained their bullish stance on RARE stock, giving a Buy rating yesterday....

1d ago

RARE

Ultragenyx Earnings Call: Clinical Wins Amid Financial Challenges

Ultragenyx Pharmaceutical, Inc. (($RARE)) has held its Q2 earnings call. Read on for the main highlights of the...

1d ago

RARE

Ultragenyx Pharmaceutical: Strong Q2 Results and Promising Future Justify Buy Rating

In a report released today, Yaron Werber from TD Cowen reiterated a Buy rating on Ultragenyx Pharmaceutical, with...

2d ago

RARE

Ultragenyx Reports Growth Amidst Strategic Advancements

Ultragenyx Pharmaceutical, Inc. ( ($RARE) ) has released its Q2 earnings. Here is a breakdown of the information...

2d ago

RARE

RARE FAQ

What was Ultragenyx Pharmaceutical, Inc.’s price range in the past 12 months?

Ultragenyx Pharmaceutical, Inc. lowest stock price was $25.81 and its highest was $60.37 in the past 12 months.

What is Ultragenyx Pharmaceutical, Inc.’s market cap?

Ultragenyx Pharmaceutical, Inc.’s market cap is $2.73B.

When is Ultragenyx Pharmaceutical, Inc.’s upcoming earnings report date?

Ultragenyx Pharmaceutical, Inc.’s upcoming earnings report date is Nov 04, 2025 which is in 88 days.

How were Ultragenyx Pharmaceutical, Inc.’s earnings last quarter?

Ultragenyx Pharmaceutical, Inc. released its earnings results on Aug 05, 2025. The company reported -$1.17 earnings per share for the quarter, beating the consensus estimate of -$1.297 by $0.127.

Is Ultragenyx Pharmaceutical, Inc. overvalued?

According to Wall Street analysts Ultragenyx Pharmaceutical, Inc.’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Ultragenyx Pharmaceutical, Inc. pay dividends?

Ultragenyx Pharmaceutical, Inc. does not currently pay dividends.

What is Ultragenyx Pharmaceutical, Inc.’s EPS estimate?

Ultragenyx Pharmaceutical, Inc.’s EPS estimate is -1.24.

How many shares outstanding does Ultragenyx Pharmaceutical, Inc. have?

Ultragenyx Pharmaceutical, Inc. has 94,542,040 shares outstanding.

What happened to Ultragenyx Pharmaceutical, Inc.’s price movement after its last earnings report?

Ultragenyx Pharmaceutical, Inc. reported an EPS of -$1.17 in its last earnings report, beating expectations of -$1.297. Following the earnings report the stock price went same N/A.

Which hedge fund is a major shareholder of Ultragenyx Pharmaceutical, Inc.?

Currently, no hedge funds are holding shares in RARE

Ultragenyx Pharmaceutical Stock Smart Score

Neutral

Fundamentals

Return on Equity

-182.60%

Trailing 12-Months

Asset Growth

-19.29%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Ultragenyx Pharmaceutical, Inc.

Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia. The company's products candidatures include DTX401, an adeno-associated virus 8 (AAV8) gene therapy clinical candidate for the treatment of patients with glycogen storage disease type Ia; DTX301, an AAV8 gene therapy for the treatment of patients with ornithine transcarbamylase; UX143, a human monoclonal antibody for the treatment of osteogenesis imperfecta; GTX-102, an antisense oligonucleotide for the treatment of Angelman syndrome; UX701, for the treatment of Wilson disease; and UX053 for the treatment of glycogen storage disease type III. Ultragenyx Pharmaceutical Inc. has collaboration and license agreement with Kyowa Kirin Co., Ltd.; Saint Louis University; Baylor Research Institute; REGENXBIO Inc.; Bayer Healthcare LLC; GeneTx; Mereo; University of Pennsylvania; Arcturus Therapeutics Holdings Inc., Solid Biosciences Inc.; and Daiichi Sankyo Co., Ltd. Ultragenyx Pharmaceutical Inc. was incorporated in 2010 and is headquartered in Novato, California.

Ultragenyx Pharmaceutical (RARE) Earnings & Revenues

Historic Earnings Reports

RARE Company Deck

RARE Earnings Call

Q2 2025

0:00 / 0:00

Earnings Call Sentiment|Positive

Ultragenyx demonstrated strong revenue growth and impressive progress across its pipeline, particularly in global markets and late-stage clinical development. However, the company also reported a significant operating loss and cash usage, with some revenue variability noted. The forward-looking statements suggest confidence in achieving full-year GAAP profitability by 2027.View all RARE earnings summaries

RARE Stock 12 Month Forecast

Average Price Target

$84.31

▲(191.53% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"27":"$27","82":"$82","137":"$137","54.5":"$54.5","109.5":"$109.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":136,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$136.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":84.31,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$84.31</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":35,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$35.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[27,54.5,82,109.5,137],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2024","6":"Feb<br/>2025","9":"May<br/>2025","12":"Aug<br/>2025","25":"Aug<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,28.44,36.713846153846156,44.98769230769231,53.261538461538464,61.535384615384615,69.80923076923077,78.08307692307693,86.35692307692308,94.63076923076923,102.90461538461538,111.17846153846153,119.4523076923077,127.72615384615385,{"y":136,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,28.44,32.737692307692306,37.035384615384615,41.33307692307692,45.63076923076923,49.92846153846154,54.22615384615385,58.52384615384615,62.821538461538466,67.11923076923077,71.41692307692308,75.71461538461539,80.01230769230769,{"y":84.31,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,28.44,28.944615384615386,29.44923076923077,29.953846153846154,30.45846153846154,30.963076923076922,31.467692307692307,31.972307692307695,32.47692307692308,32.98153846153846,33.48615384615385,33.99076923076923,34.495384615384616,{"y":35,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":44.15,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 43,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":56.78,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 34,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":56.51,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 28,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":50.99,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 33,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":47.6,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 37,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":42.07,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 34,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":43.03,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 34,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":42.92,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 32,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":33.84,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 28,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":38.97,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":36.14,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":36.26,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 41,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":28.44,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >